Thiogenesis Therapeutics Reports AGM Results and Corporate Milestones

Thiogenesis Therapeutics Corp ( (TSE:TTI) ) just unveiled an update.

Thiogenesis Therapeutics Corp recently held its Annual General Meeting of Shareholders, where all incumbent directors were re-elected, and MNP LLP was reappointed as the company’s auditor. The company announced significant clinical and regulatory milestones, including the closing of a C$4.15 million private placement to support ongoing and upcoming clinical trials. The FDA cleared an IND application for TTI-0102 in Leigh Syndrome Spectrum, and the company received scientific advice from the EMA for a planned Phase 2a trial in pediatric MASH. The company is actively enrolling patients in its Phase 2 clinical trial for MELAS and anticipates a 3-month interim analysis in October 2025. These developments position Thiogenesis to potentially deliver a differentiated therapeutic option for patients affected by oxidative stress and mitochondrial dysfunction.

More about Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. It focuses on developing sulfur-containing prodrugs for the treatment of serious pediatric diseases with unmet medical needs. The company’s lead product candidate, TTI-0102, is involved in active Phase 2 clinical trials for conditions such as Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS), Leigh Syndrome Spectrum, and is planning a trial for pediatric Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Average Trading Volume: 30,146

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$38.36M

See more data about TTI stock on TipRanks’ Stock Analysis page.